RT Journal Article
SR Electronic
T1 Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4658
DO 10.1183/13993003.congress-2019.PA4658
VO 54
IS suppl 63
A1 Rolof G.P. Gijtenbeek
A1 Gea Helfrich
A1 Ben J.W. Venmans
A1 Anneke Ten Brinke
A1 Kim De Jong
A1 Wouter H. Van Geffen
YR 2019
UL http://erj.ersjournals.com/content/54/suppl_63/PA4658.abstract
AB Introduction: Treatment regimens in stage IV NSCLC are generally assessed in a highly selected population of relatively fit and younger patients. However, the population of elderly patients (aged ≥70) with lung cancer is increasing.Objectives: To compare untreated elderly patients with stage IV NSCLC receiving chemotherapy (CT) versus best supportive care (BSC) regarding patient characteristics and overall survival and to assess if these characteristics can predict treatment tolerance.|Methods: Single center retrospective cohort study, including patients aged ≥70 years diagnosed with stage IV NSCLC between 2009-2018. Treatment tolerance was defined as completing therapy without unplanned hospitalizations. Differences in patient characteristics (age, gender, ECOG performance score (PS), and ACE-27 comorbidity score) were assessed.Results: 223 patients were included, of which 90 (40%) started first line cancer therapy of whom 70 (78%) patients received CT and 133 (60%) received BSC only. Patients receiving CT were younger (74 vs.77 years, p<0.001) with a better PS (1 vs. 2, p<0.001) and a similar comorbidity score and had a longer survival compared to those receiving BSC (median 174 vs. 50 days, p<0.001), this effect remained after adjusting for age and PS. 15 (21%) patients receiving CT finished treatment without unplanned hospitalization. There were no differences between patients who tolerated CT and those who did not.Conclusion: Treated patients were younger with a better PS, had similar comorbidities and a longer survival than patients receiving BSC. Overall treatment tolerance was poor and seemed unrelated to patient characteristics.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4658.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).